PROM1 and colorectal carcinoma: Importantly, CMab-43 exerted antitumor activity in Caco-2 ×enograft models at a dose of 100 μg/mouse/week administered three times, suggesting that CMab-43 may be useful for antibody therapy against CD133-positive CRC (26).